REG - RTW Biotech Opp. - Portfolio Company Update: Artios Pharma

RTW Biotech OpportunitiesAnnouncement

12/04/2024 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240412:nRSL5173Ka&default-theme=true

RNS Number : 5173K  RTW Biotech Opportunities Ltd  12 April 2024

LEI: 549300Q7EXQQH6KF7Z84

12 April 2024

RTW Biotech Opportunities Ltd

Portfolio Company Update: Artios Pharma

 

 ●    RTW's, Chris Liu PhD, joins the Artios Pharma Board of Directors
 ●    The Company's holding in Artios Pharma was significantly increased with the
      recent Arix transaction, making it one of the top shareholders

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed
investment company focused on identifying transformative assets with high
growth potential across the life sciences sector, is pleased to announce that
Chris Liu, PhD has been appointed to the Board of Directors at Artios Pharma
("Artios"). Chris is a Senior Research Analyst at RTW Investments, LP (the
"Investment Manager") where he leads oncology research efforts.

 

In February 2024, RTW Biotech Opportunities acquired the assets of Arix
Bioscience, plc, of which Artios Pharma was the largest position. The
transaction significantly added to the Company's existing position in Artios.
At 31 March 2024, Artios represented 4.6% of the Company's NAV.

 

Artios is a Cambridge, UK-based company developing breakthrough cancer
treatments that target DNA Damage Response (DDR) pathways to specifically
destroy certain devastating cancers that are difficult to treat.

 

Chris Liu, PhD, commented: "RTW is now a top shareholder of Artios following
the acquisition of Arix. The expansion of our equity interest reflects our
confidence and excitement in Artios' innovative platform targeting broad
aspects of the DNA damage response. I look forward to partnering with the team
and the Board to support them in their mission to bring new therapies to
patients suffering from difficult to treat solid tumors."

 

Artios' announcement can be found on their website: https://artios.com/
(https://www.artios.com/press-release/artios-pharma-bolsters-board-of-directors-with-appointment-of-chris-liu-phd/)
.

 

For Further Information

 RTW Investments, LP                                      +44 20 7959 6361
 Woody Stileman, Managing Director, Business Development  biotechopportunities@rtwfunds.com (mailto:biotechopportunities@rtwfunds.com)

 Krisha McCune, Director, Investor Relations

 Buchanan (PR & Communications Adviser)                   +44 20 7466 5107
 Charles Ryland
 Henry Wilson
 George Beale

 Deutsche Numis (Joint Corporate Broker)                  +44 20 7260 1000
 Freddie Barnfield
 Nathan Brown
 Euan Brown

 BofA Securities (Joint Corporate Broker)                 +44 20 7628 1000
 Edward Peel
 Alex Penney

 Cadarn Capital (Distribution & IR Partner)               +44 73 6888 3211
 David Harris

 Elysium Fund Management Limited                          +44 14 8181 0100

 Joanna Duquemin Nicolle, Chief Executive Officer

 Sadie Morrison, Managing Director

 Morgan Stanley Fund Services USA LLC                     +1 914 225 8885

 

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund
focused on identifying transformative assets with high growth potential across
the biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUBLGDSGSBDGSD